Is TARA or IMA more profitable?

ImageneBio's return on equity of -38.99% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -41.72% -38.78% ImageneBio N/A -38.99% -34.84%

Does the media favor TARA or IMA?

In the previous week, ImageneBio had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for ImageneBio and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.81 beat ImageneBio's score of 0.63 indicating that Protara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KROS or IMA?

In the previous week, Keros Therapeutics had 4 more articles in the media than ImageneBio. MarketBeat recorded 8 mentions for Keros Therapeutics and 4 mentions for ImageneBio. Keros Therapeutics' average media sentiment score of 1.24 beat ImageneBio's score of 0.63 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IMA or CUE?

ImageneBio currently has a consensus price target of $29.00, suggesting a potential upside of 470.87%. Given ImageneBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImageneBio is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, IMA or CUE?

Cue Biopharma has higher revenue and earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImageneBio $800K 72.07 -$45.35M -$4.58 N/A Cue Biopharma $27.47M 7.60 -$26.60M -$27.02 N/A

Is IMA or CUE more profitable?

ImageneBio has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. ImageneBio's return on equity of -38.99% beat Cue Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Cue Biopharma -435.83% -620.06% -291.15%

Does the media prefer IMA or CUE?

In the previous week, ImageneBio and ImageneBio both had 4 articles in the media. Cue Biopharma's average media sentiment score of 1.84 beat ImageneBio's score of 0.63 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is IMA or GLSI more profitable?

ImageneBio's return on equity of -38.99% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Greenwich LifeSciences N/A -793.81% -295.32%

Does the media prefer IMA or TNXP?

In the previous week, Tonix Pharmaceuticals had 12 more articles in the media than ImageneBio. MarketBeat recorded 16 mentions for Tonix Pharmaceuticals and 4 mentions for ImageneBio. Tonix Pharmaceuticals' average media sentiment score of 0.74 beat ImageneBio's score of 0.63 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ImageneBio (IMA) Competitors

$5.08 +0.07 (+1.40%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.07 -0.01 (-0.20%)

As of 09/11/2026 04:10 PM Eastern

Compare

IMA vs. TARA, KROS, CUE, GLSI, and TNXP

Should you buy ImageneBio stock or one of its competitors? ImageneBio's main competitors and comparable companies include Protara Therapeutics (TARA), Keros Therapeutics (KROS), Cue Biopharma (CUE), Greenwich LifeSciences (GLSI), and Tonix Pharmaceuticals (TNXP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImageneBio compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

ImageneBio's return on equity of -38.99% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
ImageneBio	N/A	-38.99%	-34.84%

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Protara Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Protara Therapeutics currently has a consensus price target of $26.25, suggesting a potential upside of 587.17%. ImageneBio has a consensus price target of $29.00, suggesting a potential upside of 470.87%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Protara Therapeutics is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

ImageneBio has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
ImageneBio	$800K	72.07	-$45.35M	-$4.58	N/A

In the previous week, ImageneBio had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 4 mentions for ImageneBio and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.81 beat ImageneBio's score of 0.63 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ImageneBio beats Protara Therapeutics on 8 of the 15 factors compared between the two stocks.

How does ImageneBio compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

In the previous week, Keros Therapeutics had 4 more articles in the media than ImageneBio. MarketBeat recorded 8 mentions for Keros Therapeutics and 4 mentions for ImageneBio. Keros Therapeutics' average media sentiment score of 1.24 beat ImageneBio's score of 0.63 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImageneBio has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
ImageneBio	N/A	-38.99%	-34.84%

Keros Therapeutics currently has a consensus price target of $20.50, indicating a potential upside of 85.02%. ImageneBio has a consensus price target of $29.00, indicating a potential upside of 470.87%. Given ImageneBio's higher possible upside, analysts clearly believe ImageneBio is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Keros Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Keros Therapeutics has higher revenue and earnings than ImageneBio. Keros Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.90	$87.01M	-$3.70	N/A
ImageneBio	$800K	72.07	-$45.35M	-$4.58	N/A

Summary

Keros Therapeutics beats ImageneBio on 11 of the 17 factors compared between the two stocks.

How does ImageneBio compare to Cue Biopharma?

ImageneBio (NASDAQ:IMA) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

ImageneBio has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market.

Cue Biopharma has higher revenue and earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	72.07	-$45.35M	-$4.58	N/A
Cue Biopharma	$27.47M	7.60	-$26.60M	-$27.02	N/A

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ImageneBio has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. ImageneBio's return on equity of -38.99% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Cue Biopharma	-435.83%	-620.06%	-291.15%

ImageneBio currently has a consensus price target of $29.00, suggesting a potential upside of 470.87%. Given ImageneBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImageneBio is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ImageneBio and ImageneBio both had 4 articles in the media. Cue Biopharma's average media sentiment score of 1.84 beat ImageneBio's score of 0.63 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cue Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

ImageneBio beats Cue Biopharma on 10 of the 16 factors compared between the two stocks.

How does ImageneBio compare to Greenwich LifeSciences?

ImageneBio (NASDAQ:IMA) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

ImageneBio's return on equity of -38.99% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Greenwich LifeSciences	N/A	-793.81%	-295.32%

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ImageneBio presently has a consensus target price of $29.00, suggesting a potential upside of 470.87%. Greenwich LifeSciences has a consensus target price of $69.00, suggesting a potential upside of 346.60%. Given ImageneBio's stronger consensus rating and higher probable upside, research analysts clearly believe ImageneBio is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ImageneBio had 3 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 4 mentions for ImageneBio and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.76 beat ImageneBio's score of 0.63 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ImageneBio	Positive
Greenwich LifeSciences	Very Positive

Greenwich LifeSciences has lower revenue, but higher earnings than ImageneBio. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	72.07	-$45.35M	-$4.58	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A

ImageneBio has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

Summary

ImageneBio beats Greenwich LifeSciences on 9 of the 14 factors compared between the two stocks.

How does ImageneBio compare to Tonix Pharmaceuticals?

ImageneBio (NASDAQ:IMA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ImageneBio has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. ImageneBio's return on equity of -38.99% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

ImageneBio has higher earnings, but lower revenue than Tonix Pharmaceuticals. ImageneBio is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	72.07	-$45.35M	-$4.58	N/A
Tonix Pharmaceuticals	$13.11M	15.53	-$124.02M	-$12.94	N/A

In the previous week, Tonix Pharmaceuticals had 12 more articles in the media than ImageneBio. MarketBeat recorded 16 mentions for Tonix Pharmaceuticals and 4 mentions for ImageneBio. Tonix Pharmaceuticals' average media sentiment score of 0.74 beat ImageneBio's score of 0.63 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tonix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImageneBio has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

ImageneBio currently has a consensus price target of $29.00, indicating a potential upside of 470.87%. Tonix Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 106.40%. Given ImageneBio's higher probable upside, analysts clearly believe ImageneBio is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

ImageneBio beats Tonix Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMA vs. The Competition

Export

Metric	ImageneBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$57.66M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-1.11	14.18	274.94	25.36
Price / Sales	72.07	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	0.43	15.12	10.33	6.20
Net Income	-$45.35M	-$22.86M	$3.50B	$358.50M
7 Day Performance	4.74%	-4.34%	-3.32%	-2.35%
1 Month Performance	-13.46%	0.54%	-0.53%	-3.23%
1 Year Performance	-44.42%	40.74%	23.51%	8.79%

ImageneBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMA ImageneBio	3.072 of 5 stars	$5.08 +1.4%	$29.00 +470.9%	-44.4%	$57.66M	$800K	N/A	70
TARA Protara Therapeutics	1.8128 of 5 stars	$3.83 -1.5%	$26.25 +585.4%	+21.7%	$226.33M	N/A	N/A	30
KROS Keros Therapeutics	3.6744 of 5 stars	$11.31 +1.3%	$20.50 +81.3%	-29.2%	$224.24M	$15.01M	N/A	100	Positive News Buyback Announcement Gap Up
CUE Cue Biopharma	1.0231 of 5 stars	$30.50 +1.7%	N/A	-95.7%	$221.43M	$27.47M	N/A	60	Positive News
GLSI Greenwich LifeSciences	2.7074 of 5 stars	$15.03 -5.5%	$69.00 +359.1%	+37.6%	$220.61M	N/A	N/A	3	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMA) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImageneBio (IMA) Competitors

IMA vs. TARA, KROS, CUE, GLSI, and TNXP

How does ImageneBio compare to Protara Therapeutics?

Summary

How does ImageneBio compare to Keros Therapeutics?

Summary

How does ImageneBio compare to Cue Biopharma?

Summary

How does ImageneBio compare to Greenwich LifeSciences?

Summary

How does ImageneBio compare to Tonix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImageneBio (IMA) Competitors

IMA vs. TARA, KROS, CUE, GLSI, and TNXP

How does ImageneBio compare to Protara Therapeutics?

Is TARA or IMA more profitable?

Do institutionals & insiders have more ownership in TARA or IMA?

Which has more risk and volatility, TARA or IMA?

Do analysts recommend TARA or IMA?

Which has preferable valuation & earnings, TARA or IMA?

Does the media favor TARA or IMA?

Summary

How does ImageneBio compare to Keros Therapeutics?

Does the media refer more to KROS or IMA?

Is KROS or IMA more profitable?

Do analysts prefer KROS or IMA?

Which has more risk and volatility, KROS or IMA?

Do institutionals & insiders believe in KROS or IMA?

Which has higher earnings and valuation, KROS or IMA?

Summary

How does ImageneBio compare to Cue Biopharma?

Which has more volatility and risk, IMA or CUE?

Which has better earnings and valuation, IMA or CUE?

Do institutionals and insiders hold more shares of IMA or CUE?

Is IMA or CUE more profitable?

Do analysts prefer IMA or CUE?

Does the media prefer IMA or CUE?

Summary

How does ImageneBio compare to Greenwich LifeSciences?

Is IMA or GLSI more profitable?

Do institutionals & insiders hold more shares of IMA or GLSI?

Do analysts rate IMA or GLSI?

Does the media prefer IMA or GLSI?

Which has higher valuation & earnings, IMA or GLSI?

Which has more volatility and risk, IMA or GLSI?

Summary

How does ImageneBio compare to Tonix Pharmaceuticals?

Do institutionals & insiders believe in IMA or TNXP?

Is IMA or TNXP more profitable?

Which has stronger valuation and earnings, IMA or TNXP?

Does the media prefer IMA or TNXP?

Which has more volatility & risk, IMA or TNXP?

Do analysts prefer IMA or TNXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools